Nektar Therapeutics (NKTR): Price and Financial Metrics
Today's Latest Price: $17.61 USD
Sep 25 4:00pm Add NKTR to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
NKTR Stock Summary Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; only 8.83% of US stocks have a lower such ratio. NKTR's price/sales ratio is 19.39; that's higher than the P/S ratio of 92.54% of US stocks. With a year-over-year growth in debt of -54.74%, Nektar Therapeutics's debt growth rate surpasses only 4.94% of about US stocks. Stocks with similar financial metrics, market capitalization, and price volatility to Nektar Therapeutics are CLLS, ZYME, RGNX, PRQR, and APTX. NKTR's SEC filings can be seen here. And to visit Nektar Therapeutics's official web site, go to www.nektar.com.
NKTR Price/Volume Stats
Nektar Therapeutics (NKTR) Company Bio
Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
NKTR Latest News Stream
All News Types
Commentary Corp. News Cramer Downgrade Earnings Hedge Fund Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Options Product News PT Lowered PT Raised PT Set (Bullish) PT Set (Neutral) Rating Reiterated (Bullish) Resumes Coverage (Bullish) Rumor Stock Offering
Loading, please wait...
Latest NKTR News From Around the Web
Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.
Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
Read More 'NKTR' Stories Here
NKTR Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7239 seconds.